Compare AP & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AP | NKTX |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.5M | 198.2M |
| IPO Year | 2018 | 2020 |
| Metric | AP | NKTX |
|---|---|---|
| Price | $9.21 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $10.83 |
| AVG Volume (30 Days) | 72.6K | ★ 560.9K |
| Earning Date | 11-11-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.88 |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $434,166,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.52 | N/A |
| P/E Ratio | $299.33 | ★ N/A |
| Revenue Growth | ★ 3.79 | N/A |
| 52 Week Low | $1.75 | $1.70 |
| 52 Week High | $12.81 | $3.72 |
| Indicator | AP | NKTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.01 | 31.83 |
| Support Level | $8.59 | $1.96 |
| Resistance Level | $9.84 | $2.50 |
| Average True Range (ATR) | 0.39 | 0.16 |
| MACD | 0.05 | -0.07 |
| Stochastic Oscillator | 57.97 | 12.35 |
Ampco-Pittsburgh Corp manufactures and sells engineered, high-performance specialty metal products and customized equipment utilized by industry throughout the world. It operates in two business segments, namely the Forged and Cast Engineered Products segment and the Air and Liquid Processing segment. The Forged and Cast Engineered Products segment produces forged hardened steel rolls, cast rolls, and open-die forged products. Forged hardened steel rolls are used in cold rolling mills by producers of steel, aluminum, & other metals. The Air and Liquid Processing segment includes Aerofin, Buffalo Air Handling, & Buffalo Pumps. The company generates a majority of its revenue from the Forged & Cast Engineered Products segment. It has a business presence in the United States & other countries.
Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.